BizcommunityAspen strikes R3.66bn deal for its menopause treatment
Aspen Pharmacare announced it will sell the European commercialisation rights and related intellectual property for its women’s health product, Ovestin, to Ennogen Healthcare International for $220m (approximately R3.66bn at the current exchange rate of R16.62 per US Dollar).